China A-share CRO sector jumps in afternoon trade; Wanbang Biopharma, Ruixin Biotech hit limit-up

The breadth of the move — limit-ups at two names and double-digit gains across a long list of CRO peers — points to a sector-wide re-rating rather than stock-specific news, which makes the absence of a named catalyst the most notable detail. For a contract-research complex whose fortunes track global biotech R&D spending, that kind of synchronized jump without a clear trigger is worth treating cautiously. Whether follow-through appears once the initial momentum fades, or whether a catalyst surfaces to justify it, is the open question.